Preeclampsia (PE) is a leading cause ofmaternal and neonatal
morbidity and mortality [1, 2]. It accounts for about one-third
of maternal deaths, ranking second amongst causes of pregnancy
associated deaths in industrialized countries [3, 4]. A
3- to 25-fold increased risk of abruptio placentae, thrombocytopenia,
disseminated intravascular coagulation, pulmonary
edema, and aspiration pneumonia [5] is associated with PE.
Furthermore, women with a history of PE continue to be at